Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A method for the absolute quantification of cDNA using real-time PCR.
Whelan JA, Russell NB, Whelan MA. Whelan JA, et al. Among authors: whelan ma. J Immunol Methods. 2003 Jul;278(1-2):261-9. doi: 10.1016/s0022-1759(03)00223-0. J Immunol Methods. 2003. PMID: 12957413
Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H. Michael A, et al. Clin Cancer Res. 2005 Jun 15;11(12):4469-78. doi: 10.1158/1078-0432.CCR-04-2337. Clin Cancer Res. 2005. PMID: 15958632 Clinical Trial.
Advances in prostate cancer immunotherapy.
Havranek EG, Whelan MA, Greenhalgh R, Dalgleish AG, Pandha H. Havranek EG, et al. Among authors: whelan ma. Surg Oncol. 2002 Jun;11(1-2):35-45. doi: 10.1016/s0960-7404(02)00012-9. Surg Oncol. 2002. PMID: 12031866 Review.
Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes.
Zal B, Kaski JC, Arno G, Akiyu JP, Xu Q, Cole D, Whelan M, Russell N, Madrigal JA, Dodi IA, Baboonian C. Zal B, et al. Circulation. 2004 Mar 16;109(10):1230-5. doi: 10.1161/01.CIR.0000118476.29352.2A. Epub 2004 Mar 1. Circulation. 2004. PMID: 14993140
Cancer immunotherapy: an embarrassment of riches?
Whelan M, Whelan J, Russell N, Dalgleish A. Whelan M, et al. Drug Discov Today. 2003 Mar 15;8(6):253-8. doi: 10.1016/s1359-6446(03)02633-3. Drug Discov Today. 2003. PMID: 12623239 Review.
The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model.
Labarthe MC, Halanek N, Birchall L, Russell N, Desel C, Todryk S, Peters MJ, Lucas A, Falkenberg FW, Dalgleish AG, Whelan M, Ward SJ. Labarthe MC, et al. Cancer Immunol Immunother. 2006 Mar;55(3):277-88. doi: 10.1007/s00262-005-0061-2. Epub 2005 Sep 13. Cancer Immunol Immunother. 2006. PMID: 16158275
Novel immunotherapeutic approaches to prostate cancer.
Dalgleish A, Whelan M. Dalgleish A, et al. Curr Opin Mol Ther. 2005 Feb;7(1):30-4. Curr Opin Mol Ther. 2005. PMID: 15732527 Review.
A novel murine model of allogeneic vaccination against renal cancer.
Havranek EG, Labarthe MC, Ward S, Anderson CJ, Whelan MA, Pandha H. Havranek EG, et al. Among authors: whelan ma. BJU Int. 2008 May;101(9):1165-9. doi: 10.1111/j.1464-410X.2008.07532.x. BJU Int. 2008. PMID: 18399831 Free article.
Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer.
Eaton JD, Perry MJ, Nicholson S, Guckian M, Russell N, Whelan M, Kirby RS. Eaton JD, et al. BJU Int. 2002 Jan;89(1):19-26. BJU Int. 2002. PMID: 11849155 Clinical Trial.
Cancer vaccines as a therapeutic modality: The long trek.
Dalgleish AG, Whelan MA. Dalgleish AG, et al. Among authors: whelan ma. Cancer Immunol Immunother. 2006 Aug;55(8):1025-32. doi: 10.1007/s00262-006-0128-8. Epub 2006 Feb 28. Cancer Immunol Immunother. 2006. PMID: 16506069 Review.
55 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback